相关实验视频

Updated: Jan 9, 2026

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

贝叶斯学会降低局部高级NSCLC患者的心脏风险,基于个性化放射治疗处方

Ruitao Lin¹, Mei Chen², Xiaodong Zhang³

¹Department of Biostatistics, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

International journal of radiation oncology, biology, physics

|December 9, 2025

概括

针对非小细胞肺癌 (NSCLC) 的个性化适应性辐射治疗 (PART) 可以减少心脏损伤. 这种方法使用贝叶斯模型来定制辐射剂量,从而减少心脏事件和降低hs-cTnT升高.

科学领域:

辐射瘤学辐射瘤学
心血管医学心血管医学
生物统计学生物统计学

背景情况:

针对非小细胞肺癌 (NSCLC) 的放射治疗存在心脏损伤的风险.
个体患者对心脏不良事件 (CAE) 的敏感性各不相同.
标准化的心脏辐射剂量限制可能不适合所有患者.

研究的目的:

开发和评估个性化适应性辐射治疗 (PART) 的框架,以最大限度地减少局部晚期NSCLC患者的CAE.
实施贝叶斯风险预测模型来指导心脏剂量限制.
在未来的临床试验中评估PART的可行性和有效性.

主要方法:

采用贝叶斯的持续学习和适应进行了一项前性研究.
贝叶斯个性化风险预测模型被开发用于指导心脏剂量限制.
高灵敏性心脏托波T (hs-cTnT) 升高作为CAE的替代生物标志物.

主要成果:

招募了100名局部晚期NSCLC患者;50人接受标准治疗,50人接受PART.
与标准队列 (31.9%) 相比,PART队列显示hs-cTnT升高的发生率较低 (20.5%).
在PART队列中,遵守剂量限制的患者的hs-cTnT升高明显低 (9.7%) 比超过剂量限制的患者 (46.2%).

结论:

对PART模型的临床实施是可行的,用于指导NSCLC的治疗决策.
由PART衍生的心脏平均剂量限制在临床上是相关的和有效的.
PART与hs-cTnT升高的发病率降低有关,这表明心脏损伤降低的可能性.

关键词:

贝叶斯式学习是贝叶斯式学习.心脏风险心脏风险其他非小细胞肺癌.个性化放射疗法是个性化的放射疗法.

更多相关视频

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...